Platelets in inflammation and atherogenesis

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Nording, Henry M ^a   Seizer, Peter ^a   Langer, Harald F ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Atherosclerosis; Inflammation; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; CYTOKINE; ECULIZUMAB; INTEGRIN; LIPOCORTIN 5; THROMBIN; TOLL LIKE RECEPTOR 9;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD VESSEL INJURY; COMPLEMENT SYSTEM; CPG ISLAND; DEFENSE MECHANISM; EXTRACELLULAR TRAP; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROTEIN EXPRESSION; REVIEW; SEPSIS; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE RICH PLASMA; THROMBOSIS; VASCULAR REMODELING;

EID: 84926616098     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00098     Document Type: Review

References (178)

1. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med (2011) 17(11):1423-36. doi:10.1038/nm.2515.
2. Rondina MT, Weyrich AS, Zimmerman GA. Platelets as cellular effectors of inflammation in vascular diseases. Circ Res (2013) 112(11):1506-19. doi:10.1161/CIRCRESAHA.113.300512.
3. Langer HF, Weber C, Gawaz M. The platelet-thrombosis and beyond. Thromb Haemost (2013) 110(5):857-8. doi:10.1160/TH13-09-0805.
4. Hagedorn I, Vögtle T, Nieswandt B. Arterial thrombus formation. Novel mechanisms and targets. Hämostaseologie (2010) 30(3):127-35.
5. Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost (2011) 9(s1):92-104. doi:10.1111/j.1538-7836.2011.04361.x.
6. Berndt M, Metharom P, Andrews R. Primary haemostasis: newer insights. Haemophilia (2014) 20(s4):15-22. doi:10.1111/hae.12427.
7. Etulain J, Schattner M. Glycobiology of platelet-endothelial cell interactions. Glycobiology (2014) 24(12):1252-9. doi:10.1093/glycob/cwu056.
8. Andrews RK, Berndt MC. The glycoprotein Ib-IX-V complex. In: Michelson A, editor. Platelets. 3rd ed. San Diego: Academic Press (2012). p. 195-212.
9. Bergmeier W, Piffath CL, Goerge T, Cifuni SM, Ruggeri ZM, Ware J, et al. The role of platelet adhesion receptor GPIba far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci U S A (2006) 103(45):16900-5. doi:10.1073/pnas.0608207103.
10. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med (2009) 15(6):665-73. doi:10.1038/nm.1955.
11. Nieswandt B, Varga-Szabo D, Elvers M. Integrins in platelet activation. J Thromb Haemost (2009) 7(s1):206-9. doi:10.1111/j.1538-7836.2009.03370.x.
12. Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res (2004) 114(4):221-33. doi:10.1016/j.thromres.2004.06.046.
13. Bergmeier W, Stefanini L. Platelet ITAM signaling. Curr Opin Hematol (2013) 20(5):445-50. doi:10.1097/MOH.0b013e3283642267.
14. Stefanini L, Boulaftali Y, Ouellette TD, Holinstat M, Désiré L, Leblond B, et al. Rap1-Rac1 circuits potentiate platelet activation. Arterioscler Thromb Vasc Biol (2012) 32(2):434-41. doi:10.1161/ATVBAHA.111.239194.
15. Moers A, Nieswandt B, Massberg S, Wettschureck N, Grüner S, Konrad I, et al. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med (2003) 9(11):1418-22. doi:10.1038/nm943.
16. Huang J-S, Ramamurthy SK, Lin X, Le Breton GC. Cell signalling through thromboxane A2 receptors. Cell Signal (2004) 16(5):521-33. doi:10.1016/j.cellsig.2003.10.008.
17. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem (1998) 273(4):2030-4. doi:10.1074/jbc.273.4.2030.
18. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res (2006) 99(12):1293-304. doi:10.1161/01.RES.0000251742.71301.16.
19. Fuller GL, Williams JA, Tomlinson MG, Eble JA, Hanna SL, Pöhlmann S, et al. The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade. J Biol Chem (2007) 282(17):12397-409. doi:10.1074/jbc. M609558200.
20. Suzuki-Inoue K, Fuller GL, García Á, Eble JA, Pöhlmann S, Inoue O, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood (2006) 107(2):542-9. doi:10.1182/blood-2005-05-1994.
21. May F, Hagedorn I, Pleines I, Bender M, Vögtle T, Eble J, et al. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood (2009) 114(16):3464-72. doi:10.1182/blood-2009-05-222273.
22. Gardiner E, Karunakaran D, Shen Y, Arthur J, Andrews R, Berndt M. Controlled shedding of platelet glycoprotein (GP) VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost (2007) 5(7):1530-7. doi:10.1111/j.1538-7836.2007.02590.x.
23. Gawaz MP, Loftus J, Bajt M, Frojmovic M, Plow E, Ginsberg M. Ligand bridging mediates integrin alpha IIb beta 3 (platelet GPIIB-IIIA) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest (1991) 88(4):1128. doi:10.1172/JCI115412.
24. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol (2008) 28(3):403-12. doi:10.1161/ATVBAHA.107.150474.
25. Ozaki Y, Asazuma N, Suzuki-Inoue K, Berndt MC. Platelet GPIb-IX-V-dependent signaling. J Thromb Haemost (2005) 3(8):1745-51. doi:10.1111/j.1538-7836.2005.01379.x.
26. Naik UP, Naik MU. Association of CIB with GPIIb/IIIa during outside-in signaling is required for platelet spreading on fibrinogen. Blood (2003) 102(4):1355-62. doi:10.1182/blood-2003-02-0591.
27. Munnix IC, Kuijpers MJ, Auger J, Thomassen CM, Panizzi P, van Zandvoort MA, et al. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation regulation by transient integrin activation. Arterioscler Thromb Vasc Biol (2007) 27(11):2484-90. doi:10.1161/ATVBAHA.107.151100.
28. Müller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell (2009) 139(6):1143-56. doi:10.1016/j.cell.2009.11.001.
29. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer H-U, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med (2006) 203(3):513-8. doi:10.1084/jem.20052458.
30. Semple JW, Italiano JE, Freedman J. Platelets and the immune continuum. Nat Rev Immunol (2011) 11(4):264-74. doi:10.1038/nri2956.
31. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 54(23):2129-38. doi:10.1016/j.jacc.2009.09.009.
32. Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. J Thromb Haemost (2014) 12(11):1764-75. doi:10.1111/jth.12730.
33. von Hundelshausen P, Weber C. Platelets as immune cells bridging inflammation and cardiovascular disease. Circ Res (2007) 100(1):27-40. doi:10.1161/01.RES.0000252802.25497.b7.
34. Gerdes N, Zhu L, Ersoy M, Hermansson A, Hjemdahl P, Hu H, et al. Platelets regulate CD4(+) T-cell differentiation via multiple chemokines in humans. Thromb Haemost (2011) 106(2):353-62. doi:10.1160/TH11-01-0020.
35. Elzey BD, Grant JF, Sinn HW, Nieswandt B, Waldschmidt TJ, Ratliff TL. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukoc Biol (2005) 78(1):80-4. doi:10.1189/jlb.1104669.
36. Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood (2008) 111(10):5028-36. doi:10.1182/blood-2007-06-097410.
37. Zhang X, Liu Y, Gao Y, Dong J, Mu C, Lu Q, et al. Inhibiting platelets aggregation could aggravate the acute infection caused by Staphylococcus aureus. Platelets (2011) 22(3):228-36. doi:10.3109/09537104.2010.543962.
38. Verschoor A, Neuenhahn M, Navarini AA, Graef P, Plaumann A, Seidlmeier A, et al. A platelet-mediated system for shuttling blood-borne bacteria to CD8 [alpha]+ dendritic cells depends on glycoprotein GPIb and complement C3. Nat Immunol (2011) 12(12):1194-201. doi:10.1038/ni.2140.
39. Cognasse F, Hamzeh-Cognasse H, Lafarge S, Delezay O, Pozzetto B, McNicol A, et al. Toll-like receptor 4 ligand can differentially modulate the release of cytokines by human platelets. Br J Haematol (2008) 141(1):84-91. doi:10.1111/j.1365-2141.2008.06999.x.
40. Thon JN, Peters CG, Machlus KR, Aslam R, Rowley J, Macleod H, et al. T granules in human platelets function in TLR9 organization and signaling. J Cell Biol (2012) 198(4):561-74. doi:10.1083/jcb.201111136.
41. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity (2003) 19(1):9-19. doi:10.1016/S1074-7613(03)00177-8.
42. Mariani E, Filardo G, Canella V, Berlingeri A, Bielli A, Cattini L, et al. Platelet-rich plasma affects bacterial growth in vitro. Cytotherapy (2014) 16(9):1294-304. doi:10.1016/j.jcyt.2014.06.003.
43. Fitzgerald JR, Foster TJ, Cox D. The interaction of bacterial pathogens with platelets. Nat Rev Microbiol (2006) 4(6):445-57. doi:10.1038/nrmicro1425.
44. Yeaman MR. Platelets in defense against bacterial pathogens. Cell Mol Life Sci (2010) 67(4):525-44. doi:10.1007/s00018-009-0210-4.
45. Speth C, Rambach G, Lass-Flörl C. Platelet immunology in fungal infections. Thromb Haemost (2014) 112(4):632-9. doi:10.1160/TH14-01-0074.
46. Weyrich AS, Denis MM, Schwertz H, Tolley ND, Foulks J, Spencer E, et al. mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood (2007) 109(5):1975-83. doi:10.1182/blood-2006-08-042192.
47. Rondina M, Schwertz H, Harris E, Kraemer B, Campbell R, Mackman N, et al. The septic milieu triggers expression of spliced tissue factor mRNA in human platelets. J Thromb Haemost (2011) 9(4):748-58. doi:10.1111/j.1538-7836.2011.04208.x.
48. Schwertz H, Tolley ND, Foulks JM, Denis MM, Risenmay BW, Buerke M, et al. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med (2006) 203(11):2433-40. doi:10.1084/jem.20061302.
49. Brown GT, McIntyre TM. Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1β-rich microparticles. J Immunol (2011) 186(9):5489-96. doi:10.4049/jimmunol.1001623.
50. Gambaryan S, Kobsar A, Rukoyatkina N, Herterich S, Geiger J, Smolenski A, et al. Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NF?B-I?B complex. J Biol Chem (2010) 285(24):18352-63. doi:10.1074/jbc. M109.077602.
51. Gidlöf O, van der Brug M, Öhman J, Gilje P, Olde B, Wahlestedt C, et al. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression. Blood (2013) 121(19):3908-17. doi:10.1182/blood-2012-10-461798.
52. Assinger A. Platelets and infection-an emerging role of platelets in viral infection. Front Immunol (2014) 5:649. doi:10.3389/fimmu.2014.00649.
53. Chaipan C, Soilleux EJ, Simpson P, Hofmann H, Gramberg T, Marzi A, et al. DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets. J Virol (2006) 80(18):8951-60. doi:10.1128/JVI.00136-06.
54. Pate KAM, Lyons CE, Dorsey JL, Shirk EN, Queen SE, Adams RJ, et al. Platelet activation and platelet-monocyte aggregate formation contribute to decreased platelet count during acute simian immunodeficiency virus infection in pig-tailed macaques. J Infect Dis (2013) 208(6):874-83. doi:10.1093/infdis/jit278.
55. Singh MV, Davidson DC, Jackson JW, Singh VB, Silva J, Ramirez SH, et al. Characterization of platelet-monocyte complexes in hiv-1-infected individuals: possible role in HIV-associated neuroinflammation. J Immunol (2014) 192(10):4674-84. doi:10.4049/jimmunol.1302318.
56. Iannacone M, Sitia G, Narvaiza I, Ruggeri ZM, Guidotti LG. Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Clin Vaccine Immunol (2007) 14(11):1532-5. doi:10.1128/CVI.00298-07.
57. Iannacone M, Sitia G, Isogawa M, Whitmire JK, Marchese P, Chisari FV, et al. Platelets prevent IFN-a/β-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A (2008) 105(2):629-34. doi:10.1073/pnas.0711200105.
58. Iannacone M, Sitia G, Isogawa M, Marchese P, Castro MG, Lowenstein PR, et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 11(11):1167-9. doi:10.1038/nm1317.
59. Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med (2008) 14(7):756-61. doi:10.1038/nm1780.
60. Goncalves R, Zhang X, Cohen H, Debrabant A, Mosser DM. Platelet activation attracts a subpopulation of effector monocytes to sites of Leishmania major infection. J Exp Med (2011) 208(6):1253-65. doi:10.1084/jem.20101751.
61. Vaheri A, Strandin T, Hepojoki J, Sironen T, Henttonen H, Makela S, et al. Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol (2013) 11(8):539-50. doi:10.1038/nrmicro3066.
62. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev (2007) 21(2):99-111. doi:10.1016/j.blre.2006.06.001.
63. Frenette PS, Denis CV, Weiss L, Jurk K, Subbarao S, Kehrel B, et al. P-selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med (2000) 191(8):1413-22. doi:10.1084/jem.191.8.1413.
64. Lam FW, Burns AR, Smith CW, Rumbaut RE. Platelets enhance neutrophil transendothelial migration via P-selectin glycoprotein ligand-1. Am J Physiol Heart Circ Physiol (2011) 300(2):H468-75. doi:10.1152/ajpheart.00491.2010.
65. Wong CH, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol (2013) 14(8):785-92. doi:10.1038/ni.2631.
66. Cao TM, Takatani T, King MR. Effect of extracellular pH on selectin adhesion: theory and experiment. Biophys J (2013) 104(2):292-9. doi:10.1016/j.bpj.2012.12.005.
67. Kuijper P, Torres HG, Van Der Linden J, Lammers J, Sixma J, Koenderman L, et al. Platelet-dependent primary hemostasis promotes selectin and integrin-mediated neutrophil adhesion to damaged endothelium under flow conditions. Blood (1996) 87(8):3271-81.
68. Page C, Pitchford S. Neutrophil and platelet complexes and their relevance to neutrophil recruitment and activation. Int Immunopharmacol (2013) 17(4):1176-84. doi:10.1016/j.intimp.2013.06.004.
69. Assinger A, Laky M, Schabbauer G, Hirschl AM, Buchberger E, Binder BR, et al. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. J Thromb Haemost (2011) 9(4):799-809. doi:10.1111/j.1538-7836.2011.04193.x.
70. Grommes J, Alard J-E, Drechsler M, Wantha S, Mörgelin M, Kuebler WM, et al. Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. Am J Respir Crit Care Med (2012) 185(6):628-36. doi:10.1164/rccm.201108-1533OC.
71. Hartwig H, Drechsler M, Lievens D, Kramp B, von Hundelshausen P, Lutgens E, et al. Platelet-derived PF4 reduces neutrophil apoptosis following arterial occlusion. Thromb Haemost (2014) 111(3):562-4. doi:10.1160/TH13-08-0699.
72. Gawaz M, Fateh-Moghadam S, Pilz G, Gurland HJ, Werdan K. Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest (1995) 25(11):843-51. doi:10.1111/j.1365-2362.1995.tb01694.x.
73. Andrews RK, Arthur JF, Gardiner E. Neutrophil extracellular traps (NETs) and the role of platelets in infection. Thromb Haemost (2014) 112(4):659-65. doi:10.1160/TH14-05-0455.
74. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med (2007) 13(4):463-9. doi:10.1038/nm1565.
75. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe (2012) 12(3):324-33. doi:10.1016/j.chom.2012.06.011.
76. Kraemer BF, Campbell RA, Schwertz H, Cody MJ, Franks Z, Tolley ND, et al. Novel anti-bacterial activities of β-defensin 1 in human platelets: suppression of pathogen growth and signaling of neutrophil extracellular trap formation. PLoS Pathog (2011) 7(11):e1002355. doi:10.1371/journal.ppat.1002355.
77. Jenne CN, Wong CH, Zemp FJ, McDonald B, Rahman MM, Forsyth PA, et al. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe (2013) 13(2):169-80. doi:10.1016/j.chom.2013.01.005.
78. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M, et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest (2012) 122(7):2661. doi:10.1172/JCI61303.
79. Rossaint J, Herter JM, Van Aken H, Napirei M, Döring Y, Weber C, et al. Synchronized integrin engagement and chemokine activation is crucial in neutrophil extracellular trap-mediated sterile inflammation. Blood (2014) 123(16):2573-84. doi:10.1182/blood-2013-07-516484.
80. van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol (2009) 85(2):195-204. doi:10.1189/jlb.0708400.
81. Stephen J, Emerson B, Fox KA, Dransfield I. The uncoupling of monocyte-platelet interactions from the induction of proinflammatory signaling in monocytes. J Immunol (2013) 191(11):5677-83. doi:10.4049/jimmunol.1301250.
82. Passacquale G, Vamadevan P, Pereira L, Hamid C, Corrigall V, Ferro A. Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One (2011) 6(10):e25595. doi:10.1371/journal.pone.0025595.
83. Scull CM, Hays WD, Fischer TH. Macrophage pro-inflammatory cytokine secretion is enhanced following interaction with autologous platelets. J Inflamm (Lond) (2010) 7:53. doi:10.1186/1476-9255-7-53.
84. Halvorsen B, Smedbakken LM, Michelsen AE, Skjelland M, Bjerkeli V, Sagen EL, et al. Activated platelets promote increased monocyte expression of CXCR5 through prostaglandin E2-related mechanisms and enhance the anti-inflammatory effects of CXCL13. Atherosclerosis (2014) 234(2):352-9. doi:10.1016/j.atherosclerosis.2014.03.021.
85. Xiang B, Zhang G, Guo L, Li X-A, Morris AJ, Daugherty A, et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun (2013) 4:2657. doi:10.1038/ncomms3657.
86. Gudbrandsdottir S, Hasselbalch HC, Nielsen CH. Activated platelets enhance IL-10 secretion and reduce TNF-α secretion by monocytes. J Immunol (2013) 191(8):4059-67. doi:10.4049/jimmunol.1201103.
87. Li N. Platelet-lymphocyte cross-talk. J Leukoc Biol (2008) 83(5):1069-78. doi:10.1189/jlb.0907615.
88. Diacovo TG, Catalina MD, Siegelman MH, Von Andrian UH. Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficient mice. J Exp Med (1998) 187(2):197-204. doi:10.1084/jem.187.2.197.
89. Zamora C, Cantó E, Nieto JC, Ortiz MA, Diaz-Torné C, Diaz-Lopez C, et al. Functional consequences of platelet binding to T lymphocytes in inflammation. J Leukoc Biol (2013) 94(3):521-9. doi:10.1189/jlb.0213074.
90. León-Ponte M, Ahern GP, O'Connell PJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood (2007) 109(8):3139-46. doi:10.1182/blood-2006-10-052787.
91. Katsounas A, Schlaak JF, Lempicki RA. CCL5: a double-edged sword in host defense against the hepatitis C virus. Int Rev Immunol (2011) 30(5-6):366-78. doi:10.3109/08830185.2011.593105.
92. Elzey BD, Ratliff TL, Sowa JM, Crist SA. Platelet CD40L at the interface of adaptive immunity. Thromb Res (2011) 127(3):180-3. doi:10.1016/j.thromres.2010.10.011.
93. Liu CY, Battaglia M, Lee SH, Sun Q-H, Aster RH, Visentin GP. Platelet factor 4 differentially modulates CD4+ CD25+ (regulatory) versus CD4+ CD25-(nonregulatory) T cells. J Immunol (2005) 174(5):2680-6. doi:10.4049/jimmunol.174.5.2680.
94. Shi G, Field DJ, Ko KA, Ture S, Srivastava K, Levy S, et al. Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. J Clin Invest (2014) 124(2):543. doi:10.1172/JCI71858.
95. Danese S, de la Motte C, Reyes BMR, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol (2004) 172(4):2011-5. doi:10.4049/jimmunol.172.4.2011.
96. Langer HF, Daub K, Braun G, Schönberger T, May AE, Schaller M, et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscler Thromb Vasc Biol (2007) 27(6):1463-70. doi:10.1161/ATVBAHA.107.141515.
97. Hagihara M, Higuchi A, Tamura N, Ueda Y, Hirabayashi K, Ikeda Y, et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol (2004) 172(9):5297-303. doi:10.4049/jimmunol.172.9.5297.
98. Hamzeh-Cognasse H, Cognasse F, Palle S, Chavarin P, Olivier T, Delézay O, et al. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. BMC Immunol (2008) 9(1):54. doi:10.1186/1471-2172-9-54.
99. Nakanishi T, Inaba M, Inagaki-Katashiba N, Tanaka A, Vien PTX, Kibata K, et al. Platelet-derived RANK ligand enhances CCL17 secretion from dendritic cells mediated by thymic stromal lymphopoietin. Platelets (2014):1-7. doi:10.3109/09537104.2014.920081.
100. Kissel K, Berber S, Nockher A, Santoso S, Bein G, Hackstein H. Human platelets target dendritic cell differentiation and production of proinflammatory cytokines. Transfusion (2006) 46(5):818-27. doi:10.1111/j.1537-2995.2006.00802.x.
101. Panigrahi S, Ma Y, Hong L, Gao D, West XZ, Salomon RG, et al. Engagement of platelet toll-like receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis. Circ Res (2013) 112(1):103-12. doi:10.1161/CIRCRESAHA.112.274241.
102. Massberg S, Brand K, Grüner S, Page S, Müller E, Müller I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med (2002) 196(7):887-96. doi:10.1084/jem.20012044.
103. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation (2001) 104(13):1533-7. doi:10.1161/hc3801.095588.
104. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med (2009) 15(1):97-103. doi:10.1038/nm.1898.
105. Strüßmann T, Tillmann S, Wirtz T, Bucala R, von Hundelshausen P, Bernhagen J, et al. Platelets are a previously unrecognised source of MIF. Thromb Haemost (2013) 110(5):1004-13. doi:10.1160/TH13-01-0049.
106. Daub K, Seizer P, Stellos K, Krämer BF, Bigalke B, Schaller M, et al. Oxidized LDL-activated platelets induce vascular inflammation. Semin Thromb Hemost (2010) 36(02):146-56. doi:10.1055/s-0030-1251498.
107. Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood (2003) 101(7):2661-6. doi:10.1182/blood-2002-07-2209.
108. Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood (2010) 116(20):4317-27. doi:10.1182/blood-2010-01-261206.
109. Mause SF, Weber C. Microparticles protagonists of a novel communication network for intercellular information exchange. Circ Res (2010) 107(9):1047-57. doi:10.1161/CIRCRESAHA.110.226456.
110. Gawaz M, Brand K, Dickfeld T, Pogatsa-Murray G, Page S, Bogner C, et al. Platelets induce alterations of chemotactic and adhesive properties of endothelial cells mediated through an interleukin-1-dependent mechanism. Implications for atherogenesis. Atherosclerosis (2000) 148(1):75-85. doi:10.1016/S0021-9150(99)00241-5.
111. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol (2001) 154(3):485-90. doi:10.1083/jcb.200105058.
112. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest (2005) 115(12):3378-84. doi:10.1172/JCI27196.
113. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost (2011) 106(5):827. doi:10.1160/TH11-08-0592.
114. Simon DI. Inflammation and vascular injury: basic discovery to drug development. Circ J (2011) 76(8):1811-8. doi:10.1253/circj. CJ-12-0801.
115. Simon DI, Chen Z, Xu H, Li CQ, Dong JF, McIntire LV, et al. Platelet glycoprotein Iba is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med (2000) 192(2):193-204. doi:10.1084/jem.192.2.193.
116. Manthey HD, Zernecke A. Dendritic cells in atherosclerosis: functions in immune regulation and beyond. Thromb Haemost (2011) 106(5):772. doi:10.1160/TH11-05-0296.
117. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 11(9):785-97. doi:10.1038/ni.1923.
118. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Des (2004) 10(2):203-11. doi:10.2174/1381612043453441.
119. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood (2007) 109(2):422-30. doi:10.1182/blood-2006-04-001206.
120. Peerschke E, Yin W, Grigg S, Ghebrehiwet B. Blood platelets activate the classical pathway of human complement. J Thromb Haemost (2006) 4(9):2035-42. doi:10.1111/j.1538-7836.2006.02065.x.
121. Peerschke EI, Yin W, Ghebrehiwet B. Platelet mediated complement activation. Adv Exp Med Biol (2008) 632:81-91.
122. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol (2010) 47(13):2170-5. doi:10.1016/j.molimm.2010.05.009.
123. Bäck J, Huber Lang M, Elgue G, Kalbitz M, Sanchez J, Nilsson Ekdahl K, et al. Distinctive regulation of contact activation by antithrombin and C1-inhibitor on activated platelets and material surfaces. Biomaterials (2009) 30(34):6573-80. doi:10.1016/j.biomaterials.2009.07.052.
124. Hamad OA, Nilsson PH, Wouters D, Lambris JD, Ekdahl KN, Nilsson B. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol (2010) 184(5):2686-92. doi:10.4049/jimmunol.0902810.
125. Patzelt J, Mueller K, Breuning S, Karathanos A, Schleicher R, Seizer P, et al. Expression of anaphylatoxin receptors on platelets in patients with coronary heart disease. Atherosclerosis (2015) 238(2):289-95. doi:10.1016/j.atherosclerosis.2014.12.002.
126. Verschoor A, Langer HF, Pan R, Wang J, Nardi M, Li Z, et al. Crosstalk between platelets and the complement system in immune protection and disease. Thromb Haemost (2013) 110(5):910-9. doi:10.1160/TH13-02-0102.
127. McCarthy MJ, Loftus IM, Thompson MM, Jones L, London NJ, Bell PR, et al. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg (1999) 30(2):261-8. doi:10.1016/S0741-5214(99)70136-9.
128. von Birgelen C, Klinkhart W, Mintz GS, Papatheodorou A, Herrmann J, Baumgart D, et al. Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same vessel: an intravascular ultrasound study in vivo. J Am Coll Cardiol (2001) 37(7):1864-70. doi:10.1016/S0735-1097(01)01234-7.
129. Tenaglia AN, Peters KG, Sketch MH Jr, Annex BH. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J (1998) 135(1):10-4. doi:10.1016/S0002-8703(98)70336-9.
130. Slevin M, Turu MM, Rovira N, Luque A, Baldellou M, Krupinski J, et al. Identification of a 'snapshot' of co-expressed angiogenic markers in laser-dissected vessels from unstable carotid plaques with targeted arrays. J Vasc Res (2009) 47(4):323-35. doi:10.1159/000265566.
131. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med (2003) 349(24):2316-25. doi:10.1056/NEJMoa035655.
132. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol (2005) 25(10):2054-61. doi:10.1161/01.ATV.0000178991.71605.18.
133. Hutter R, Valdiviezo C, Sauter BV, Savontaus M, Chereshnev I, Carrick FE, et al. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages evidence for apoptosis as link between inflammation and atherothrombosis. Circulation (2004) 109(16):2001-8. doi:10.1161/01.CIR.0000125526.91945.AE.
134. Fernández-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol (1994) 23(7):1562-9. doi:10.1016/0735-1097(94)90657-2.
135. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Ferna A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation (1997) 95(3):594-9. doi:10.1161/01.CIR.95.3.594.
136. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation (1999) 99(14):1780-7. doi:10.1161/01.CIR.99.14.1780.
137. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood (2005) 105(1):192-8. doi:10.1182/blood-2004-06-2225.
138. Bhattacharjee G, Ahamed J, Pedersen B, El-Sheikh A, Mackman N, Ruf W, et al. Regulation of tissue factor-mediated initiation of the coagulation cascade by cell surface grp78. Arterioscler Thromb Vasc Biol (2005) 25(8):1737-43. doi:10.1161/01.ATV.0000173419.31242.56.
139. Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ (2013) 22(6):399-411. doi:10.1016/j.hlc.2013.03.001.
140. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation (1995) 92(6):1565-9.
141. Geng Y-J, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol (1995) 147(2):251.
142. Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction an intravascular ultrasound study. Circulation (2004) 110(22):3424-9. doi:10.1161/01.CIR.0000148131.41425.E9.
143. Maldonado N, Kelly-Arnold A, Vengrenyuk Y, Laudier D, Fallon JT, Virmani R, et al. A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability: potential implications for plaque rupture. Am J Physiol Heart Circ Physiol (2012) 303(5):H619-28. doi:10.1152/ajpheart.00036.2012.
144. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation (2002) 105(9):1135-43. doi:10.1161/hc0902.104353.
145. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J (2011) 162(4):597-605. doi:10.1016/j.ahj.2011.06.012.
146. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost (2009) 7(1):332-9. doi:10.1111/j.1538-7836.2009.03404.x.
147. Gaziano JM, Greenland P. When should aspirin be used for prevention of cardiovascular events? JAMA (2014) 312(23):2503-4. doi:10.1001/jama.2014.16047.
148. Verheugt FW, Gersh BJ. Aspirin beyond platelet inhibition. Am J Cardiol (2002) 90(1):39-41. doi:10.1016/S0002-9149(02)02383-4.
149. Cyrus T, Sung S, Zhao L, Funk CD, Tang S, Praticò D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation (2002) 106(10):1282-7. doi:10.1161/01.CIR.0000027816.54430.96.
150. Tous M, Ferré N, Vilella E, Riu F, Camps J, Joven J. Aspirin attenuates the initiation but not the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet. Basic Clin Pharmacol Toxicol (2004) 95(1):15-9. doi:10.1111/j.1742-7843.2004.pto950104.x.
151. Paul-Clark MJ, van Cao T, Moradi-Bidhendi N, Cooper D, Gilroy DW. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med (2004) 200(1):69-78. doi:10.1084/jem.20040566.
152. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science (1994) 265(5174):956-9. doi:10.1126/science.8052854.
153. Steinhubl SR, Badimon JJ, Bhatt DL, Herbert J-M, Lüscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med (2007) 12(2):113-22. doi:10.1177/1358863X07077462.
154. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA (2014) 312(23):2510-20. doi:10.1001/jama.2014.15690.
155. Huynh K. Atherosclerosis: low-dose aspirin failed to improve cardiovascular outcomes. Nat Rev Cardiol (2015) 12(1):3. doi:10.1038/nrcardio.2014.194.
156. Li M, Zhang Y, Ren H, Zhang Y, Zhu X. Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis (2007) 194(2):348-56. doi:10.1016/j.atherosclerosis.2006.11.006.
157. Afek A, Kogan E, Maysel-Auslender S, Mor A, Regev E, Rubinstein A, et al. Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvasc Res (2009) 77(3):364-9. doi:10.1016/j.mvr.2009.01.009.
158. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol (2004) 93(6):679-84. doi:10.1016/j.amjcard.2003.11.048.
159. Ramadan R, Dhawan SS, Syed H, Pohlel FK, Binongo JN, Ghazzal ZB, et al. Effects of clopidogrel therapy on oxidative stress, inflammation, vascular function, and progenitor cells in stable coronary artery disease. J Cardiovasc Pharmacol (2014) 63(4):369-74. doi:10.1097/FJC.0000000000000057.
160. Azar RR, Kassab R, Zoghbi A, Aboujaoudé S, El-Osta H, Ghorra P, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J (2006) 151(2):521.e1-4. doi:10.1016/j.ahj.2005.10.021.
161. Klinkhardt U, Bauersachs R, Adams J, Graff J, Lindhoff-Last E, Harder S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther (2003) 73(3):232-41. doi:10.1067/mcp.2003.13.
162. Xiao Z, Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol (2004) 43(11):1982-8. doi:10.1016/j.jacc.2003.10.071.
163. Waehre T, Damås J, Pedersen T, Gullestad L, Yndestad A, Andreassen A, et al. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost (2006) 4(10):2140-7. doi:10.1111/j.1538-7836.2006.02131.x.
164. Nagy B Jr, Miszti-Blasius K, Kerenyi A, Clemetson KJ, Kappelmayer J. Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation. Curr Med Chem (2012) 19(4):518-31. doi:10.2174/092986712798918770.
165. Subbanagounder G, Leitinger N, Shih PT, Faull KF, Berliner JA. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis in vitro and in vivo inhibition by WEB 2086. Circ Res (1999) 85(4):311-8. doi:10.1161/01.RES.85.4.311.
166. Ewing MM, de Vries MR, Nordzell M, Pettersson K, de Boer HC, van Zonneveld AJ, et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol (2011) 31(1):95-101. doi:10.1161/ATVBAHA.110.216747.
167. Hamad OA, Bäck J, Nilsson PH, Nilsson B, Ekdahl KN. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Adv Exp Med Biol (2012) 946:185-205. doi:10.1007/978-1-4614-0106-3_11.
168. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol (2007) 25(11):1265-75. doi:10.1038/nbt1342.
169. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 190(8):3839-47. doi:10.4049/jimmunol.1203200.
170. Hill A, Hillmen P, Richards SJ, Elebute D, Marsh JC, Chan J, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood (2005) 106(7):2559-65. doi:10.1182/blood-2005-02-0564.
171. Röth A, Hock C, Konik A, Christoph S, Dührsen U. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena. Int J Hematol (2011) 93(6):704-14. doi:10.1007/s12185-011-0867-y.
172. Lindberg S. Prognostic utility of the soluble CD40 ligand in acute coronary syndrome. Coron Artery Dis (2014) 25(7):548-9. doi:10.1097/MCA.0000000000000155.
173. Setianto BY, Hartopo AB, Achadiono DN, Gharini PP. Association between levels of circulating soluble CD40 ligand on admission and in-hospital events among acute coronary syndrome patients. Acta Med Indones (2011) 43(2):82-7.
174. Pusuroglu H, Akgul O, Erturk M, Uyarel H, Bulut U, Akkaya E, et al. Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Coron Artery Dis (2014) 25(7):558-64. doi:10.1097/MCA.0000000000000142.
175. Zhao W, Zhang F, Li Z, Yu H, Li Z, Gao W. Soluble CD40 ligand is associated with angiographic severity of coronary artery disease in patients with acute coronary syndrome. Chin Med J (2014) 127(12):2218-21. doi:10.3760/cma.j.issn.0366-6999.20133159.
176. Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med (2011) 43(5):331-40. doi:10.3109/07853890.2010.546362.
177. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation (2001) 103(4):491-5. doi:10.1161/01.CIR.103.4.491.
178. Kisucka J, Chauhan AK, Zhao B-Q, Patten IS, Yesilaltay A, Krieger M, et al. Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood (2009) 113(23):6015-22. doi:10.1182/blood-2008-10-186650.